Death Halts Sensipar Trials in Kids
(MedPage Today) -- The FDA today suspended all pediatric clinical trials of cinacalcet hydrochloride (Sensipar) -- Amgen's calcium-sensing receptor agonist -- because of the death of a 14-year-old patient in one of the studies.
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Calcium | Children | Clinical Trials | Health | International Medicine & Public Health | Pediatrics | Sensipar | Study